

Ref. No.: LASA/SE/17-18/051

Wednesday February 14, 2018

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
----------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub. : Press Release

With reference to the above subject, please find enclosed Press release on the financial performance of our Company for the Q3 FY18.

Request you to take the same on record and acknowledge receipt.


Thanking you,

Yours Truly,

For Lasa Supergenerics Limited

for

HITESH WADHWANI
COMPANY SECRETARY



Encl: As above



Media Release

Q3 FY18 Net Revenue at Rs. 61 crore

Q3 FY18 EBITDA at Rs. 14 crore & EBITDA Margin at 22%

Q3 FY18 PAT at Rs. 3 crore & Q3 FY18 PAT Margin at 5%

Q3 FY18 EPS at Rs. 1.36

Mumbai, February 14, 2018: Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, today, announced its unaudited results for the quarter and nine months ended December 31, 2017.

Our Company is pleased to announce its third quarter and nine months ended unaudited financial results for the financial year ended 2017-18. We continue to remain focused towards further doing more backward integration within our product portfolio. Our Company is constantly making every effort to add new and new molecules.

At the same time our continuous focus on research and development, timely delivery, consistent and excellent quality has resulted in constant and increasing demand. The above mentioned focus areas have been the trademark and our biggest strength which has led to increased confidence of clients leading to a continuous flow of orders.

CIDC Update - CIDIC has recognized Lasa Supergenerics as their 'First Choice Customer'

The Company shook hands with China's CIDIC group. CIDIC Co. Ltd. is one of the Pharma giants in China. Both the companies have entered into a synergistic and symbiotic business association. At the same time Lasa gets high growth opportunity to enter into newer markets. This is a win-win business arrangement for both the companies. The deal will positively impact the margins of Lasa Supergenerics by effectively reducing the manufacturing cost and favorably enhancing sales in South East Asian Countries, owing to quality of the products and goodwill of new business partner in these territories. This is another essential step towards meeting desired targets. The Company is in a phase of evolution and growth and the Company will strive hard and deliver on the expected lines



CIDIC has recognized Lasa Supergenerics as their 'First Choice Customer', enabling us to source intermediates at very competitive prices from China & Japan and on longer credit terms. This will also help LASA Supergenerics to source the right material at right price for its products. CIDIC will sell LASA Supergenerics finished goods to South East Asian Countries. CIDIC has significant recognition in these territories for supply of quality products.

9M FY18 Financial Results Highlights

- **Net Revenue** was at **Rs. 187.1 crore** in 9M FY18
- **EBITDA** was at **Rs. 44.7 crore** in 9M FY18
- **EBITDA Margin** stood at **24.0%** in 9M FY18
- **Profit After Tax** was at **Rs. 18.8 crore** in 9M FY18
- **PAT Margin** stood at **10.1%** in 9M FY18
- **EPS** Stood at **Rs. 8.23** in 9M FY18

Management Comments:

Commenting on the quarterly and nine monthly unaudited results, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

"The financial for year to date has been in line with our expectation in terms of revenue and profitability. We are glad to focus on new and innovative product which has been effectively helping us to bag new orders in newer geographies and grow our business worldwide. We also witnessed a lot of traction from different geographies for API's. I am very pleased to inform that "Lasa Supergenerics Ltd." shook hands with China's "CIDIC Group". CIDIC Co. Ltd. is one of the Pharma giants in China. Apart from this with the help of strong in-house R&D facility we continue to remain focused on developing advanced catalyst chemistry for our molecules to enhance its productivity.

I thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."

About Lasa Supergenerics Limited:

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer



Lasa Supergenerics Limited

and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: www.lasalabs.com

For any Investor Relations query, please contact:

Dr. Omkar Herlekar Chairman & Managing Director Lasa Supergenerics Ltd. Email: investor@lasalabs.com	Amit Sharma Bridge Investor Relations Pvt. Ltd. Phone: +91-22-26873003 Email: amit@bridge-ir.com
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*